SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors weigh significant year-over-year revenue growth and a strong order backlog against high operational expenses and an earnings miss. While some community members view the dip as a strategic opportunity to capitalize on the company's long-term scaling, others remain focused on the impact of high short interest and market volatility surrounding the earnings results.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending following the official delivery and acceptance of its Horizon 1 AI data center by Microsoft, alongside achieving NVIDIA Exemplar Cloud status. Investors are actively debating the stock's long-term derisking versus short-term price suppression, with community sentiment split between high expectations for institutional growth and frustration over persistent short interest.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is facing significant volatility as investors debate the impact of a recent earnings miss, missed revenue targets, and concerns over future dilution to fund production timelines. While some members of the community are calling for a bearish outlook and focusing on potential liquidity issues, others view the sharp pullback as a buying opportunity, highlighting the company's substantial $1.8 billion backlog and its long-term strategic position in the space infrastructure sector.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors digest the transition away from TDAPA reimbursement and monitor potential future catalysts, including upcoming REZZAYO clinical data and ongoing commercial negotiations with large dialysis operators. While some community members express frustration over management's communication and the stock's recent performance, others are closely tracking institutional accumulation and legislative efforts to support long-term adoption of the company's anti-infective portfolio.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors monitor ongoing institutional accumulation and anticipation of a Q4 BLA submission for its prostate cancer therapy. The community is actively discussing the potential clinical impact of the company's multimodal immunotherapy platform and interpreting manufacturing and regulatory updates provided during recent investor presentations.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is trending as investors react to a fiscal fourth-quarter beat and strong forward guidance that highlights a "networking supercycle" driven by $7.5 billion in AI infrastructure orders. While the stock faced a post-earnings selloff, the community is actively debating whether this represents an overcorrection against elevated expectations or a strategic dip in a high-quality name supported by widespread analyst price target upgrades.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell is experiencing heightened market activity driven by massive demand for AI-optimized server hardware, supported by bullish analyst sentiment and strong read-throughs from industry peers. The community is actively discussing the valuation gap between Dell and other AI infrastructure players while debating whether the stock's recent price appreciation is sustainable or if it is currently overextended.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion Inc. (INFQ) is trending due to anticipation surrounding its earnings report, with the community closely tracking revenue growth, government contract progress, and the potential for a short squeeze as institutional interest rises. Investors are actively debating the company's long-term potential in the quantum sector and are closely monitoring management's commentary for signs of a breakout.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems (CBRS) is experiencing significant volatility following a second-quarter earnings report that missed revenue and EPS expectations, despite raising full-year guidance and highlighting long-term capacity expansion plans. The community is sharply divided, with some investors viewing the post-earnings pullback as a compelling buying opportunity, while others remain skeptical due to concerns over high valuation, heavy reliance on anchor tenants, and upcoming share lockup expirations.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is trending following a recent quarterly report that showcased revenue growth but missed some analyst expectations, leading to volatility as the market evaluates the pace of its commercial launch. Investors and community members are actively debating the company's ability to scale ZEVASKYN patient treatments and achieve monthly profitability, with attention focused on the onboarding of new qualified treatment centers as the primary driver for future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised

Novavax beat Q2 earnings and revenue estimates, raises its 2026 adjusted revenue outlook, cuts expense guidance and outlines potential Sanofi milestones ahead.

NVAX Stock Holds Steady As Novavax Lifts Revenue Outlook On Licensing Pivot — Retail Eyes Buyout, More Partnership Deals  

Equity

Novavax raised its full-year 2026 adjusted total revenue outlook to $235–$275 million from $230–$270 million.


ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness

ADMA Biologics matches earnings estimates, misses on revenues and maintains its 2026 outlook as strong Asceniv growth offsets continued pressure on Bivigam.

Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates

Novavax (NVAX) delivered earnings and revenue surprises of +11.11% and +13.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging  Novavax (NVAX) This Year?

Here is how Novavax (NVAX) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

Novavax Slips To Loss In Q2 On Reduced Revenue, Cuts FY26 Guidance

(RTTNews) - On Thursday, Novavax, Inc. (NVAX), a biotechnology company, reported a slip to loss in the second quarter, due to lower total revenue generated, compared to the prior year. Further, the company lowered its guidance for fiscal 2026...

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights PR Newswire GAITHERSBURG, Md., Aug. 6, 2026 Reported total revenue of $57 million for the second quarter of 2026 and raised full-year...

HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up 

HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.

NVAX Stock Rises Ahead Of Q2 Earnings As Focus Shifts To Licensing Deals

Novavax is scheduled to release its second-quarter 2026 financial results before the U.S. market opens on Thursday.


Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026

Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026 Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026 PR Newswire GAITHERSBURG, Md., July 30, 2026 GAITHERSBURG, Md., July 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the...

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.23	--	--	N/A
Q2 '26	-$0.38	-$0.32	15.75%	BEAT
Q1 '26	-$0.24	-$0.06	75.18%	BEAT
Q4 '25	-$0.48	$0.11	122.69%	BEAT
Q3 '25	-$1.20	-$1.25	-4.49%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings